| abstract |
Use of a lanreotide for the manufacture of a medicament useful for the treatment of a disease or condition characterized in that it comprises administering a patient in need thereof, an effective amount of the compound H-beta-D-Nal-Cys-Tyr-D-Trp- Lys-Val-Cys-Thr-NH (also known as lanreotide) where the two cysteines are linked by a disulfide bond or a pharmaceutically acceptable salt thereof, where the disease or condition is selected from the group consisting of systemic sclerosis, pancreatic ascites, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison syndrome, scleroderma hypersecretory diarrhea, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, complications of potal hypertension, obstruction of the small intestine, gastroesophageal reflux, duodenal reflux syndrome, duodenal reflux syndrome, duodenal reflux syndrome Cushing, gonadotropinoma, hyperparathyroidism, diabetic neuropathy, d macular degeneration, hypercalcemia of malignancy, Paget's disease, cancer cachexia meningioma, hypotension and panic attacks, use of a lanreotide for the manufacture of a drug and a pharmaceutical composition that comprises it. |